Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6 mice potential for treatment of pseudoxanthoma elasticum

Clinical and Translational Science

Volumn 2, Issue 6, 2009, Pages 398-404

  Li, Qiaoli ^a   LaRusso, Jennifer ^a   Grand Pierre, Alix E ^a   Uitto, Jouni ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Heritable mineralization disorders; Phosphate binders Abcc6 mouse; Pseudoxanthoma elasticum

Indexed keywords

CALCIUM; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; DEMINERALIZATION; DIET SUPPLEMENTATION; HISTOPATHOLOGY; MAGNESIUM BLOOD LEVEL; MORPHOMETRICS; MOUSE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; SKIN BIOPSY; VIBRISSA;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CONNECTIVE TISSUE; DIET; FEMUR; LANTHANUM; MAGNESIUM; MICE; MICE, INBRED C57BL; MINERALS; PHOSPHATES; PHOSPHORUS; PSEUDOXANTHOMA ELASTICUM; TOMOGRAPHY, X-RAY COMPUTED; VIBRISSAE;

MUS;

EID: 77953454937     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00161.x     Document Type: Article

References (31)

1. Li Q, Jiang Q, Pfendner E, Váradi A, Uitto J. Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol. 2009, 18:1-11.
2. Georgalas I, Papaconstantinou D, Koutsandrea C, Kalantzis G, Karagiannis D, Georgopoulos G, Ladas I. Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag. 2009, 5:81-89.
3. Lebwohl M, Halperin J, Phelps RG. Occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. N Engl J Med. 1993, 329:1237-1239.
4. Neldner KH. Pseudoxanthoma elasticum. Clin Dermatol. 1988, 6:1-159.
5. Pfendner EG, Vanakker O, Terry SF, Vourthis S, McAndrew P, McLain MR, Fratta S, Marais AS, Hariri S, Coucke PJ, Ramsey M, Viljoen D, Tery PF, Uitto J, Bercovitch LG. Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum. J Med Genet. 2007, 44:621-628.
6. Iliás A, Urban Z, Seidl TL, Le Saux O, Sinkó E, Boyd CD, Sarkadi B, Váradi A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002, 277:16860-16867.
7. Vanakker OM, Martin L, Gheduzzi D, Leroy BP, Loeys BL, Guerci VI, Matthys D, Terry SF, Coucke PJ, Pasquali-Ronchetti I, De Paepe A. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol. 2007, 27:581-587.
8. Li Q, Schurgers L, Smith A, Tsokos M, Uitto J, Cowen E. Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency. Am J Pathol. 2009, 174:534-540.
9. Berkner KL. The vitamin K-dependent carboxylase. Ann Rev Nutr. 2005, 25:127-149.
10. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Mtab Care. 2000, 3:433-438.
11. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386:78-81.
12. Borst P, van de Wetering K, Schlingemann R. Does the absence of ABCC6 (multidrug resistance protein 6) in patients with pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery?. Cell Cycle. 2008, 7:1575-1579.
13. Hendig D, Arndt M, Szliska C, Kleesiek K, Götting C. SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem. 2007, 53:829-836.
14. Schöen S, Schulz V, Prante C, Hendig D, Szaliska C, Kuhn J, Kleesiek K, Götting C. Polymorphisms in the xylosyltransferase genes cause higher serum XT-I activity in patients with pseudoxanthoma elasticum (PXE) and are involved in a severe disease course. J Med Genet. 2006, 43:745-749.
15. Zarbock R, Hendig D, Szliska C, Kleesiek K, Götting C. Pseudoxanthoma elasticum: genetic variations in antioxidant genes are risk factors for early disease onset. Clin Chem. 2007, 53:1734-1740.
16. Li Q, Grange D, Armstrong N, Whelan A, Hurley M, Rishavy M, Hallgren K, Berkner K, Schurgers L, Jiang Q, Uitto J. Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes. J Invest Dermatol. 2007, 129:553-563.
17. Renie WA, Pyeritz RE, Combs J, Fine SL. Pseudoxanthoma elasticum: high calcium intake in early life correlates with severity. Am J Med Genet. 1984, 19:235-244.
18. Uitto J, Pulkkinen L, Ringpfeil F. Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder at the environment-genome interface?. Trends Mol Med. 2001, 7:13-17.
19. Hutchinson AJ. Oral phosphate binders. Kidney Int. 2009, 75:906-914.
20. Sherer DW, Singer G, Uribarri J, Phelps RG, Sapadin AN, Freund KB, Yanuzzi L, Fuchs W, Lebwohl M. Oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol. 2005, 53:610-615.
21. Klement JF, Matsuzaki Y, Jiang Q-J, Terlizzi J, Choi HY, Fujimoto N, Li K, Pulkkinen L, Birk DE, Sundberg JP, Uitto J. Targeted ablation of the ABCC6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol. 2005, 25:8299-8310.
22. LaRusso J, Jiang Q, Li Q, Uitto J. Ectopic mineralization of connective tissue in Abcc6 -/-mice: effects of dietary modifications and a phosphate binder-a preliminary study. Exp Dermatol. 2008, 17:203-207.
23. Siegel S, Castellan N. Nonparametric Statistics for the Behavioral Sciences 1988, 180-181. Singapore, McGraw-Hill
24. Jiang Q, Li Q, Uitto J. Aberrant mineralization of connective tissues in a mouse model of pseudoxanthoma elasticum: systemic and local regulatory factors. J Invest Dermatol. 2007, 127:1392-1402.
25. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ. Lanthanum carbonate. Ann Pharma-cother. 2006, 40:234-240.
26. Hutchinson AJ, Barnett ME, Krause R, Kwan JTC, Siami GA. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008, 110:15-23.
27. Riond JL, Hartmann P, Steiner P, Ursprung R, Wanner M, Forrer R, Spichiger UE, Thomsen JS, Mosekilde L. Long-term excessive magnesium supplementation is deleterious whereas suboptimal supply is beneficial for bones in rats. Magnes Res. 2000, 13:249-264.
28. Rude RK, Kirchen ME, Gruber HE, Stasky AA, Meyer MH. Magensium defiency induces bone loss in the rat. Miner Electrolyte Metab. 1998, 24:314-320.
29. Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PWF, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in eldery men and women. Am J Clin Nutr. 1999, 69:727-736.
30. Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J Nutr. 2003, 133:2879-2882.
31. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Tren Mol Med. 2009, 15:405-416.